Biolase: Vergessene Aktie ist am erwachen , wie geht es weiter ?? - 500 Beiträge pro Seite


ISIN: US0909112072 | WKN: A2JLZ6 | Symbol: BIOL
0,491
$
01:00:00
Nasdaq
-8,91 %
-0,048 USD

Beitrag schreiben

Begriffe und/oder Benutzer

 

Schaut man sich die Entwicklung des Papiers in den letzten Tagen an, so kann man nur sagen:

Bemerkenswert !

Selbst an Tagen wo radikal bergab ging legt diese Aktie zu.
Wo legen die Ursachen für diese Performance ?

- ist diese Papier massiv unterbewertet ?
- war es der postive Newsflow der letzten Tage ?
- oder sind es Insiderkäufe, die sich nun rechtzeitg eindecken, da das Geschäftsmodell nun doch funktioniert ?

Ich denke es ist es auf jden Fall Wert diese Aktie mal
genauer zu beobachten und zu diskutieren.

Meinungen dazu ?

GruÃ
massel

Ps: Infos zum Unternehmen findet Ihr sehr einfach über Google, einfach "Biolase" eingeben...
Antwort auf Beitrag Nr.: 36.723.957 von Massel am 08.03.09 12:03:54
Eventl. weil sie vor 5 Jahren noch bei 15E stand, gerade ein ATL markiert hat -&eine Aktie irgenwann auch einfach mal steigt??

Popeye
Antwort auf Beitrag Nr.: 36.724.406 von Popeye82 am 08.03.09 14:12:51nunja, das der Wert "ausgebombt" ist kann man unschwer am Chart erkennen.

Stellt sich nur die Frage: zurecht so tief ?

oder haben wir hier eine krasse Unterbewertung vorliegen ?

Vielleicht gibt es ja jemanden der sich schon früher mit der Aktie
beschäftigt hat und über die Ursachen des Kursverlaufs was sagen kann ?

Gruß
massel
Source: BIOLASE Technology, Inc.

BIOLASE Conference Call: 2008 Fourth Quarter and Year-End Results
BIOLASE to Host Conference Call, March 16 At 4:30 p.m. ET
IRVINE, Calif., March 9, 2009 (GLOBE NEWSWIRE) -- BIOLASE Technology, Inc. (Nasdaq:BLTI), the world's leading dental laser company, announced today that the Company will host a conference call on Monday, March 16 at 4:30 p.m. Eastern Time to discuss its operating results for the fourth quarter and year ended December 31, 2008 and to answer questions. The Company's results release will be distributed at approximately 4:05 p.m. Eastern Time that same day.

Phone Participation

To listen to the conference call live via telephone, please dial 1-800-762-8973 from the U.S. or, for international callers, please dial +1-480-629-1990, approximately 10 minutes before the start time.

Webcast Participation

To listen to the conference call live via the Internet, visit the Investors section of the BIOLASE website at www.biolase.com. Please go to the website 15 minutes prior to the call to register, download and install the necessary audio software.

Replay

An audio archive of the webcast will be available for one year on the Investors section of the BIOLASE website.

About BIOLASE Technology, Inc.

BIOLASE Technology, Inc. (http://www.biolase.com), the world's leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.

CONTACT: Allen & Caron
Jill Bertotti
+1-949-474-4300
trotz miserabler Zahlen für 2008, die gestern veröffentlich wurden,
(0,38 US Verlust pro Aktie) und vorallem nicht getroffen Analystenerwartungen zieht die Aktie weiter an.... hätte ich nicht gedacht...:confused::confused:

Scheint doch noch unterbewertet zu sein...

gruß
massel

----------------------------------------------------------
Biolase Technology Q4 Loss Widens - Update
3/16/2009 5:05 PM ET

RELATED NEWS



Biolase Technology Q4 Loss Widens - Quick Facts





BIOLASE Technology Q4 & Year-End Earnings Conference Call At 4:30 PM





BIOLASE Technology names Frederick Capallo Interim CFO - Quick Facts





Biolase Technology CEO Jake St. Philip Resigns; David Mulder Named Successor - Update





BIOLASE CEO Jake Philip resigns; CFO Mulder named successor - Quick facts



(RTTNews) - Monday, Biolase Technology, Inc. (BLTI: News ), a medical technology company, reported a wider loss for the fourth quarter, as revenues declined from last year impacted by adverse macroeconomic factors.

The Irvine, California-based company posted a net loss $5.29 million or $0.22 per share for the quarter, wider than net loss of $1.15 million or $0.05 per share in the same period a year ago. Two analysts polled by Thomson Reuters expected the company to post a loss of $0.11 per share. Analysts' estimates typically exclude special items.

Net revenue for the quarter declined to $11.64 million from $20.84 million in the previous year. The Street anticipated revenues of $13.53 million.

David Mulder, Biolase chief executive officer said, "The top line result for Biolase as for most medical capital equipment suppliers has been impacted substantially by macroeconomic factors from late summer through today."

For fiscal 2008, the company reported a wider net loss of $9.1 million or $0.38 per share, compared to net loss of $7.3 million or $0.31 per share in the previous year. Full year revenues slipped to $64.62 million from $66.9 million last year. Analysts anticipated net loss of $0.27 per share on revenues of $66.53 million for the year.

BLTI closed Monday's trading up $0.14 or 17.95% at $0.92 on a volume of about 83 thousand shares.
Hallo,

bei dem Verlauf der Aktie von Biolase wundert mich, dass hier in diesem Thread nichts passiert.
Antwort auf Beitrag Nr.: 40.976.542 von MaatMod am 03.02.11 15:49:12Da sag ich mal DANKE !!
----------

Meine erste Kostolany-Aktie... Schön unters Kopfkissen gelegt und die letzten
Tage nachgeschaut..:D:D

-Marktkap. ca. 100 Mio
-28 Mio Aktien draußen
-Turnaround geschafft

und heute eine die nächste fette News:

http://www.marketwire.com/press-release/BIOLASE-Receives-CE-…

SOURCE: BIOLASE Technology, Inc.

Feb 03, 2011 09:00 ET
BIOLASE Receives CE Mark Approval for Waterlase® iPlusTM All-Tissue Laser

Commercial Sales Initiated in Europe

IRVINE, CA--(Marketwire - February 3, 2011) - BIOLASE Technology, Inc. (NASDAQ: BLTI), the World's leading dental laser manufacturer and distributor, today announced that it has received Conformite Europeene (CE) Mark approval for the Waterlase® iPlus™ System dual-wavelength all-tissue laser. The Waterlase iPlus, BIOLASE's new flagship laser product, is the most advanced laser in the market and the first major breakthrough in all-tissue laser technology since the Waterlase MD™ was introduced in 2005. Receipt of CE Mark enables BIOLASE to initiate commercial sales of the system throughout the European Union.

"While BIOLASE is currently accepting orders on both the newly launched Waterlase iPlus and our revolutionary iLase™ battery-operated, wireless handheld laser, the products will be formally introduced in Europe at the world's largest dental meeting, the International Dental Show (IDS), in Cologne, Germany, being held March 22-26, 2011," said Chairman and CEO Federico Pignatelli. The Waterlase iPlus and iLase will be in Hall 4.2, stand L060/M061 in the American Pavilion.

BIOLASE is headquartered in Irvine, California, and also maintains a European sales and support subsidiary in Germany, BIOLASE EUROPE GMBH, to cover the European and Middle Eastern markets, and is in the process of setting up an Asian sales and support operation based in Shanghai, China, to cover the rapidly growing Asia-Pacific region. The Company also plans to open a subsidiary in South America in the first quarter of 2011. In North America, the Company is distributing on a direct mode and also through Henry Schein, Inc. (NASDAQ: HSIC) and Benco Dental. Schein International is a distributor in select European countries, Australia and New Zealand.

Pignatelli added, "We are moving very rapidly to commercialize our new flagship laser in all major markets and are encouraged with the speed to which we received this approval. We currently have 26 distributors in Europe, Eastern Europe and the Middle East plus Schein International in Germany, Austria, France, Spain, Portugal, Italy, Belgium, Luxembourg, the Netherlands and the UK."

The Waterlase iPlus, with its Intuitive Power Control, not only addresses the key functional needs for the next generation of laser dentists, but it also delivers double the power and cutting speed with unparalleled control and versatility for all laser dentist users, experienced or novice. Performing most types of procedures with the new Waterlase iPlus provides minimal to no pain or discomfort, minimizes the need for local anesthetic in most restorative cases, eliminates the risk of cross-contamination associated with conventional drills and burs, and results in preserving the tissue biologically intact, and without causing the damaging micro-fractures of the tooth structure and avoiding the necrosis caused by heat and abrasion.

About BIOLASE Technology, Inc.
BIOLASE Technology, Inc., the World's leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.

For updates and information on laser and Waterlase dentistry, find BIOLASE at http://www.biolase.com, Twitter at http://twitter.com/GoWaterlase, and YouTube at http://www.youtube.com/user/Rossca08.

-------------------------
Gruß
massel
Modern Lasers Used to Reduce Pain and Increase Treatment Effectiveness
Contact Information
Dr. Oleg Klempner, DDS
200 Central Park South, Suite 109
New York, 10019
212-265-2021
http://www.200centralparkdental.com


Midtown Manhattan dental practice, Central Park South Dental Care has switched over to the latest Biolase MD lasers to effectively treat gum disease.
Online PR News – 07-February-2011 –Midtown Manhattan dental practice, Central Park South Dental Care has switched over to the latest Biolase MD lasers to effectively treat gum disease.
Central Park South Dental Care treats their patients with minimal discomfort and remarkable efficiency with the exclusive use of laser technology. Dr. Oleg Klempner uses the latest generation lasers for all aspects of his practice.
Lasers have replaced drills, providing so many advantages. Lasers have more precise control and all procedures can be performed more accurately with less trauma to the patient.


Dr. Klempner says, “Less than 5% of dentists use lasers in their practice. We switched to the new Biolase MD laser because it was the system approved by the FDA for gum disease. The laser gum treatment as compared to the traditional periodontal surgery doesn't require any cutting or stitching of the gums. This greatly reduces postoperative swelling and discomfort, plus the healing time is much faster.”
Lasers are minimally invasive and reduce bleeding. A patient can recover much faster from any procedure. The greatest benefit for the patient is minimal to zero pain. Also, swelling is reduced significantly from any procedure with minimal amounts of anesthesia.
Dr. Klempner also uses lasers in all of his cosmetic procedures, producing outstanding results.
In the case of teeth whitening he says, “Laser teeth whitening causes NO sensitivity and is accomplished in half the time of traditional in-house whitening.” With cosmetic gum lifts he says, “The procedure is accomplished, thanks to the modern laser technology, without having to use a scalpel or sutures.
The use of lasers makes for a great office experience. Coming back is something to look forward to instead of the typical dreaded experience. Most patients require nothing stronger than over the counter medication afterwards.
Modern Lasers used in select dental practices like Central Park South Dental Care, have drastically changed the effectiveness, comfort and safety of each procedure. It will continue to change the way people perceive going to a dentist.
About Central Park South Dental Care:
Dr. Oleg Klempner and his dedicated dental team have been serving the Greater New York area which includes Queens, Rego Park, Manhattan, and NYC. His practice specializes in Cosmetic dentistry. To learn more visit: http://www.200centralparkdental.com or call 212- 265-2021
---------

Gruß
massel
Antwort auf Beitrag Nr.: 41.842.922 von RichyBerlin am 25.07.11 22:37:00Aus der Nähe betrachtet

Antwort auf Beitrag Nr.: 41.861.643 von RichyBerlin am 28.07.11 21:23:06hmm...unter beide Linien gefallen... gar net gut...
:rolleyes:
Jetzt könnts klappen



Heute Aktienrückkaufprogramm bekanntgegeben. Bis zu 2 Mio.Shares.

Und Zahlen:

Press Release Source: BIOLASE Technology, Inc. On Wednesday August 10, 2011, 9:00 am EDT

IRVINE, CA--(Marketwire -08/10/11)- BIOLASE Technology, Inc. (NASDAQ: BLTI - News) --

$12.1 Million in Q2 Revenue, up 105 Percent Year over Year
Q2 GAAP Loss of $753,000, or $0.03 Loss per Share
Q2 Non-GAAP Profit of $6,000, or $0.00 per Share, Third Consecutive Quarter of Non-GAAP Profit, First Time Since the Second Quarter of 2004
Revenue Guidance of $14.0 Million - $15.0 Million for Q3, up from $6.2 Million, Year over Year

BIOLASE Technology, Inc., the World's leading dental laser manufacturer and distributor, today reported unaudited operating results for its second quarter and six months ended June 30, 2011.

Net revenue for this year's second quarter was $12.1 million, up 105 percent from $5.9 million in the same quarter for 2010 and up 14 percent sequentially from $10.6 million in the first quarter of 2011. These increases were driven by BIOLASE's return to a direct sales and multi-distributor business model which was implemented during the fourth quarter of 2010. Net revenue for the first six months of 2011 was $22.6 million, up 120 percent from $10.3 million in the prior year period. Approximately 63 percent of BIOLASE's revenues for the second quarter and 53 percent of revenues for the six months ended June 30, 2011, were from the sale of its all-tissue Waterlase systems, the majority of which have been the newly introduced, revolutionary Waterlase iPlus™. Sales of BIOLASE's diode laser systems made up approximately 14 percent and 24 percent of total revenues during the second quarter and six months ended June 30, 2011, respectively. Excluding royalties of $390,000 and $1.1 million in the second quarter of 2011 and 2010, respectively, net revenue increased $6.9 million, or 146 percent, period over period.

As announced in July, approximately $2 million of orders received in the second quarter were unable to be shipped by June 30, 2011, primarily due to the timing of a significant change order placed by Henry Schein, Inc. (NASDAQ: HSIC - News) and the resulting delays of critical components. During the early part of the third quarter, BIOLASE completely fulfilled the final portion of its two irrevocable purchase orders from Schein which originally totaled $9 million.

The percentage of net revenue in this year's second quarter from the U.S. and international markets totaled approximately 71 percent and 29 percent, respectively, as compared to approximately 60 percent and 40 percent of net revenue in the prior year comparable period. In April 2011, BIOLASE announced that it had also regained full rights to sell and/or distribute its products in all international markets which were previously exclusive markets of Schein. As a result, BIOLASE is now selling through multiple distributors, with the ability to sell direct, in those markets on a go-forward basis. As the Company has spent the first two quarters of the year reorganizing its international sales model, BIOLASE has experienced a reduction in its international sales as a percentage of total sales. International sales are expected to substantially increase as a percentage of total sales on a go-forward basis.

Federico Pignatelli, Chairman and CEO, said, "The rate of revenue growth and operational progress at the Company continued to accelerate in the second quarter and our momentum going into the second half of the year is strong. Sales activities across our laser product platforms remained very active -- especially in the case of the Waterlase iPlus, which we believe will become the most successful all-tissue dental laser in history. In addition, we are now taking orders and will soon be shipping the first units from our new BIOLASE DaVinci Imaging™ product line. We believe that the launch of imaging will not only benefit revenues, but will create additional synergy and higher utilization of our sales force investment for years to come. Our launch into the dental digital imaging capital equipment market allows us to leverage our valuable brand and existing install base and offer a perfect complement to our laser devices which is the next logical step in offering dentists our Total Technology Solution™."

Recent Highlights
A series of recent actions, developments and key accomplishments include the following:

The receipt of first orders for the Company's new state-of-the-art BIOLASE DaVinci Imaging dental imaging devices for delivery in the third quarter. These products cover a wide range of applications and range in price from $3,000 to $125,000.
The hiring of Richard Whipp as Director of Operations. Whipp's experience with lean manufacturing and supply chain management has made an immediate positive impact on the Company's supply chain and production flow.
The opening of Asian headquarters in Shanghai, China, and a direct sales and service office in Mumbai, India.
The receipt of approximately $9.024 million from institutional investors in a private placement during June 2011 through the sale of 1,625,947 shares of common stock and an aggregate number of warrants to purchase up to 812,974 shares of common stock.
The increase of BIOLASE's Net Equity from a stockholders' deficit of approximately $3.5 million at September 30, 2010, to positive stockholders' net equity of $14.9 million at June 30, 2011, an increase of $18.4 million in the past nine months.
The award of three new patents that significantly strengthened the intellectual property surrounding the Company's core laser technology and extended it well into 2026 while augmenting protection for many newer features and alternatives such as more laser wavelengths.
The award of two new patents directly related to treating presbyopia, a condition suffered by 2.5 billion people worldwide, giving BIOLASE one of the widest ranges of applications and coverage in the field. BIOLASE remains focused on obtaining by 2013 the grant of an Investigational Device Exemption using this technology.
The receipt of MDB Capital Group's (MDB's) ASTRUM Award for the Company's innovation and development of numerous disruptive technologies. BIOLASE was selected from MDB's 2011 group of "Best and Brightest" small-cap companies, a group that is advancing some of today's most innovative and market-leading intellectual property.
The declaration of a 1 percent stock dividend payable on June 30, 2011 to stockholders of record on June 10, 2011.
The inclusion of BIOLASE in the Russell 2000® and Russell Global Indexes when Russell Investments reconstituted its comprehensive set of U.S. and global equity indexes on June 24, 2011.
Dismissal of all of the claims made by Philips Electronics (NYSE: PHG - News) and Discus Dental LLC against the Company, whereby they claimed that the BIOLASE's iLase™ personal laser infringed Discus' design patent, as well as trade dress rights Discus claimed in its own dental lasers. Such claims were dismissed in their entirety with prejudice with the court on July 12, 2011.

Gross profit as a percentage of net revenue for this year's second quarter and first six months was 46.5 percent and 46.2 percent, respectively, compared to 32.8 percent and 21.4 percent for the prior year comparable periods. Gross profit increased as a percent of net revenue from 45.8 percent in the first quarter of 2011 to 46.5 percent in this year's second quarter despite additional production costs and expedite fees. The year-over-year increases were primarily due to higher sales volumes as a result of expanding the Company's product offering, better utilization of fixed costs, and reduced expenses, offset by the decline in Procter & Gamble royalty revenue.

Operating expenses in the 2011 second quarter and first six months were $6.3 million and $11.6 million, respectively, compared to $6.1 million and $11.6 million in the year-earlier periods.

The net loss for the second quarter of 2011 totaled $753,000, or a loss of $0.03 per share, compared to a net loss of $4.2 million, or a loss of $0.17 per share, in the second quarter of 2010. After removing interest expense of $6,000, non-cash depreciation and amortization expenses of $183,000, and non-cash stock-based compensation expense of $570,000, this year's second quarter resulted in an adjusted non-GAAP net income of $6,000, or $0.00 per share, for the second quarter of 2011 compared with a non-GAAP net loss of $3.7 million, or a loss of $0.15 per share, for the second quarter of 2010. This is the first time since the second quarter of 2004 that BIOLASE has generated three consecutive quarters of non-GAAP net income.

The net loss for the first six months of 2011 was $1.5 million, or a loss of $0.06 per share, compared to a net loss of $9.5 million, or a loss of $0.38 per share, for the year-earlier period. Non-GAAP net income was $98,000, or $0.00 per share, for this year's first six months compared with a non-GAAP net loss of $8.5 million, or a loss of $0.34 per share, for the same period in 2010.

As of June 30, 2011, cash and cash equivalents totaled $10.1 million and shareholders' equity was $14.9 million.


Beitrag zu dieser Diskussion schreiben


Es handelt sich hier um eine ältere Diskussion, daher ist das Schreiben in dieser Diskussion nicht mehr möglich. Bitte eröffnen Sie hier eine neue Diskussion.